Procedural and one-year clinical outcomes of bioresorbable vascular scaffolds for the treatment of chronic total occlusions: A single-centre experience

Cardiovascular Journal of Africa

Volumn 27, Issue 6, 2016, Pages 345-349

  Özel, Erdem ^a   Tastan, Ahmet ^b   Öztürk, Ali ^b   Özcan, Emin Evren ^c   Kilicaslan, Baris ^a   Özdogan, Öner ^a  

^a Tepecik Training and Research Hospital   (Turkey)

^b SIFA UNIVERSITY   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Bioresorbable vascular scaffold; Chronic total occlusion; Percutaneous coronary intervention

Indexed keywords

ADULT; AGE; ANGINA PECTORIS; ARTICLE; BIORESORBABLE SCAFFOLD; BLOOD VESSEL DIAMETER; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OCCLUSION; DEATH; DIABETES MELLITUS; DRUG WITHDRAWAL; DUAL ANTIPLATELET THERAPY; FEMALE; FLUOROSCOPY; FOLLOW UP; GENDER; HEART INFARCTION; HUMAN; INCIDENCE; MALE; MICROCATHETER; OUTCOME ASSESSMENT; REVASCULARIZATION; RIGHT CORONARY ARTERY; ADVERSE EFFECTS; AGED; BIODEGRADABLE IMPLANT; CHRONIC DISEASE; CORONARY ANGIOGRAPHY; CORONARY OCCLUSION; DEVICES; DIAGNOSTIC IMAGING; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; RISK FACTOR; TIME FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TURKEY;

ANTITHROMBOCYTIC AGENT;

ABSORBABLE IMPLANTS; AGED; ANGINA PECTORIS; ANGIOPLASTY, BALLOON, CORONARY; CHRONIC DISEASE; CORONARY ANGIOGRAPHY; CORONARY OCCLUSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSTHESIS DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TURKEY;

EID: 85006024638     PISSN: 19951892     EISSN: None     Source Type: Journal    
DOI: 10.5830/CVJA-2016-033     Document Type: Article

References (23)

1. Di Mario C, Werner GS, Sianos G, et al. European perspective in the recanalisation of chronic total occlusions (CTO): Consensus document from the EuroCTO Club. EuroIntervention 2007; 3(1): 30-43.
2. Fefer P, Knudtson ML, Cheema AN, et al. The Canadian Multicenter Chronic Total Occlusions Registry. Current perspectives on coronary chronic total occlusions. J Am Coll Cardiol Mar 2012; 59(11): 991-997.
3. Claessen BE, Dangas GD, Godino C, et al. Long-term clinical outcomes of percutaneous coronary intervention for chronic total occlusions in patients with vs. without diabetes mellitus. Am J Cardiol 2011; 108(7): 924-931.
4. Joyal D, Afilalo J, Rinfret S. Effectiveness of recanalization of chronic total occlu- sions: A systematic review and meta-analysis. Am Heart J 2010; 160(1): 179-187.
5. Grantham JA, Jones PG, Cannon L, Spertus JA. Quantifying the early health status benefits of successful chronic total occlusion recanalization: Results from the Flow-Cardia's Approach to Chronic Total Occlusion Recanalization (FACTOR) Trial. Circ Cardiovasc Qual Outcomes 2010; 3(3): 284-290.
6. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37): 2541-2619.
7. Colmenarez HJ, Escaned J, Fernandez C, et al. Efficacy and safety of drug-eluting stents in chronic total coronary occlusion recanalization: A systematic review and meta-analysis. J Am Coll Cardiol 2010; 55(17): 1854-1866.
8. Patel MR, Marso SP, Dai D, et al. Comparative effectiveness of drugeluting vs. bare-metal stents in elderly patients undergoing revascularization of chronic total coronary occlusions: Results from the National Cardiovascular Data Registry, 2005-2008. J Am Coll Cardiol Cardiovasc Interv 2012; 5(10): 1054-1061.
9. Serruys PW, Chevalier B, Dudek D, et al. A bioresorbable everolimuseluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet 2015; 385: 43-54.
10. Ellis SG, Kereiakes DJ, Metzger DC, et al. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015, Oct 12. [Epub ahead of print].
11. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J 2015, Sep 1. pii: Ehv435. [Epub ahead of print].
12. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimuseluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009; 373(9667): 897-910.
13. Dudek D, Onuma Y, Ormiston JA, et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention 2012; 7: 1060-1061.
14. Wiebe J, Liebetrau C, Dorr O, et al. Feasibility of everolimus-eluting bioresorbable vascular scaffolds in patients with chronic total occlusion. Int J Cardiol 2015; 179: 90-94.
15. Goktekin O, Yamac AH, Latib A, et al. Evaluation of the safety of everolimus-eluting bioresorbable vascular scaffold (BVS) implantation in patients with chronic total coronary occlusions: Acute procedural and short-term clinical results. J Invasive Cardiol 2015; 27: 461-466.
16. Ojeda S, Pan M, Romero M, et al. Outcomes and computed tomography scan follow-up of bioresorbable vascular scaffold for the percutaneous treatment of chronic total coronary artery occlusion. Am J Cardiol 2015; 115: 1487-1493.
17. Rama-Merchan JC, Mattesini A, Dall'Ara G, Mario CD. Chronic total occlusion successfully treated with a bioresorbable everolimus-eluting vascular scaffold. Postepy Kardiol Interwencyjnej 2014; 10: 128-129.
18. Galassi AR, Brilakis ES, Boukhris M, et al. Appropriateness of percutaneous revascularization of coronary chronic total occlusions: An overview. Eur Heart J 2015, Aug 7. pii: Ehv391. [Epub ahead of print].
19. Ito T, Tsuchikane E, Nasu K, et al. Impact of lesion morphology on angiographic and clinical outcomes in patients with chronic total occlusion after recanalization with drug-eluting stents: A multislice computed tomography study. Eur Radiol 2015; 25: 3084-3092.
20. Ozel E, Tastan A, Ozturk A, Ozcan EE, Uyar S, Senarslan O. What is better for predilatation in bioresorbable vascular scaffold implantation: A non-compliant or a compliant balloon? Anatol J Cardiol 2015, Jun 18.
21. doi: 10.5152/Anatol J Cardiol.2015.6184. [Epub ahead of print]. 21. Caiazzo G, Kilic ID, Fabris E, et al. Absorb bioresorbable vascular scaffold: What have we learned after 5 years of clinical experience? Int J Cardiol 2015; 201: 129-136.
22. Tamburino C, Latib A, van Geuns RJ, et al. Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: A European perspective. EuroIntervention 2015; 11: 45-52.
23. Morino Y, Abe M, Morimoto T, et al. Predicting successful guidewire crossing through chronic total occlusion of native coronary lesions within 30 minutes: The J-CTO (Multicenter CTO Registry in Japan) score as a difficulty grading and time assessment tool. J Am Coll Cardiol Cardiovasc Interv 2011; 4: 213-221.